Anti-interleukin-6 (tocilizumab) therapy in Takayasu’s arteritis: a real life experience
Levent KilicÖmer KaradağAbdulsamet ErdenAlper SariArmagan BerkanGözde Kübra YardimciEsra FiratUmut KalyoncuŞaziye Şule Apraş BilgenSedat KirazAli Ihsan ErtenliAli AkdoganPublished in: Turkish journal of medical sciences (2020)
Based on retrospective real life data, anti-IL-6 (tocilizumab) appears to be an effective and tolerable treatment option in refractory TA patients.